Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C29H32N8O |
| Molecular Weight | 508.6174 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=C(C=N1)C2=CC=C(CNC3=CC(=NC=N3)C4=CN=C5C=C(OCCCN6CCCC6)C=CN45)C=C2
InChI
InChIKey=LVMAULGVWBINFP-UHFFFAOYSA-N
InChI=1S/C29H32N8O/c1-35-20-24(18-34-35)23-7-5-22(6-8-23)17-30-28-16-26(32-21-33-28)27-19-31-29-15-25(9-13-37(27)29)38-14-4-12-36-10-2-3-11-36/h5-9,13,15-16,18-21H,2-4,10-12,14,17H2,1H3,(H,30,32,33)
| Molecular Formula | C29H32N8O |
| Molecular Weight | 508.6174 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 10:15:28 GMT 2025
by
admin
on
Wed Apr 02 10:15:28 GMT 2025
|
| Record UNII |
Y6UHU32G5Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
892122
Created by
admin on Wed Apr 02 10:15:28 GMT 2025 , Edited by admin on Wed Apr 02 10:15:28 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000043439
Created by
admin on Wed Apr 02 10:15:28 GMT 2025 , Edited by admin on Wed Apr 02 10:15:28 GMT 2025
|
PRIMARY | |||
|
155587867
Created by
admin on Wed Apr 02 10:15:28 GMT 2025 , Edited by admin on Wed Apr 02 10:15:28 GMT 2025
|
PRIMARY | |||
|
Y6UHU32G5Z
Created by
admin on Wed Apr 02 10:15:28 GMT 2025 , Edited by admin on Wed Apr 02 10:15:28 GMT 2025
|
PRIMARY | |||
|
2590556-80-0
Created by
admin on Wed Apr 02 10:15:28 GMT 2025 , Edited by admin on Wed Apr 02 10:15:28 GMT 2025
|
PRIMARY | |||
|
C190128
Created by
admin on Wed Apr 02 10:15:28 GMT 2025 , Edited by admin on Wed Apr 02 10:15:28 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
|
TARGET -> INHIBITOR |
IC50
|
||
|
|
TARGET -> INHIBITOR |
IC50
|
||
|
|
TARGET -> INHIBITOR |
IC50
|
||
|
|
TARGET -> INHIBITOR |
IC50
|
||
|
|
TARGET -> INHIBITOR |
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
M4205 is planned for clinical development for the treatment of patients with unresectable metastatic or recurrent gastrointestinal stromal tumors (GIST). GIST are the most common human sarcomas and driven by activating mutations in cKIT (~80%) and the related PDGFRA (~5% to 10%) receptor tyrosine kinases
|